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Cells use the interferon-induced, double-stranded-RNA-dependent protein kinase PKR as a defense against
virus infections. Upon activation, PKR phosphorylates and thereby inactivates the protein synthesis initiation
factor eIF-2, resulting in the cessation of protein synthesis. Viruses have evolved various strategies to coun-
teract this cellular defense. In this paper, we show that simian virus 40 (SV40) large-T antigen can antagonize
the translational inhibitory effect resulting from the activation of PKR in virus-infected cells. Unlike the
situation with other virus-host cell interactions, SV40 large-T antigen does not block the activation of PKR,
suggesting that SV40 counteracts the cellular antiviral response mediated by PKR at a step downstream of
PKR activation. Mutational analysis of large-T antigen indicates that a domain located between amino acids
400 and 600 of large-T antigen is responsible for this function. These results define a novel translational
regulatory function for the SV40 large-T antigen.
Interferon-induced, double-stranded-RNA-activated pro-
tein kinase PKR (also referred to as p68 kinase, double-strand-
ed-RNA-activated inhibitor [DAI], and eIF-2a kinase) is an
enzyme that cells use as a defense against virus infections.
PKR, upon activation, phosphorylates and thereby inactivates
the vital protein synthesis initiation factor eIF-2 (reviewed in
references 22, 23, 36, 44, and 47). The initiation factor eIF-2 is
required at one of the earliest steps in translational initiation.
During polypeptide chain initiation, eIF-2 forms a ternary
complex with GTP and tRNAMet. In the subsequent step of the
initiation pathway, the GTP moiety bound to eIF-2 is hydro-
lyzed to GDP, which is then exchanged for GTP before the
eIF-2 can function in a new round of initiation. This exchange
reaction is carried out by another factor, termed eIF-2B. PKR
acts by phosphorylating eIF-2, which then forms a tight com-
plex with the limiting amounts of eIF-2B, preventing the recy-
cling of eIF-2 and thereby reinitiation of protein synthesis (42).
Viruses must overcome this cellular antiviral response for
successful infection (reviewed in references 23, 36, and 44).
Different viruses have evolved different strategies to combat
the translation inhibitory effects resulting from PKR activation.
The best studied is the strategy used by adenoviruses (Ad),
which use an RNA polymerase III-directed small RNA, which
binds to and inactivates PKR (reviewed in references 37, 47,
and 54). In cells infected with Ad mutants lacking the VAI
RNA gene, protein synthesis is dramatically reduced as a result
of PKR activation. We previously showed that simian virus
(SV40) can rescue the translational defect in monkey cells that
results from infection of an Ad mutant lacking the VA RNA
genes (51). We now report that this complementation function
is encoded by the large-T gene and that the complementation
occurs at the level of the protein. Surprisingly, unlike what
occurs with other viruses, large-T antigen of SV40 does not
prevent the activation of PKR and the complementation ap-
pears to occur at a step downstream of PKR activation. Using
mutational analysis, we have identified a domain in the C-
terminal region of large-T antigen that is responsible for the
complementation. These results define a novel translational
regulation function for the SV40 large-T antigen.
MATERIALS AND METHODS
Cells, viruses, and plasmids. Human 293, A549 (a human lung carcinoma cell
line), CV-1p, and COS cells (CV-1 cells stably transformed with the SV40 early
region) were maintained in Dulbecco’s modified Eagle medium (DME) contain-
ing 10% calf serum (CV-1p and A549) or fetal calf serum (293 and COS cells).
The Ad5 mutants used in this study are mutant dl704, which is a phenotypically
wild-type (WT) variant which does not code for the minor VAII RNA species;
mutant sub722, which does not code for the major VAI RNA and grows to a
20-fold-reduced titer; and mutant sub720, which lacks both the VAI and VAII
RNA genes and grows to a 100-fold-reduced titer in comparison with the WT
virus (5–7, 17). All of the Ad stocks were propagated in A549 cells.
Following are the details of the SV40 mutants used in this study. Mutant dl888
does not synthesize the small-t protein because of a 100-bp deletion which
overlaps the splice donor site of the message that codes for small-t antigen (41a,
49). Mutants dl1263 and dl1265 contain deletions in the C-terminal region of the
large-T gene; they are defective for the Ad helper function of SV40, each
retaining about 33 and 8% of the activity, respectively (14, 21). dl1263 has a 33-bp
in-frame deletion that extends from map units 0.195 to 0.201 and causes the
large-T antigen to shorten by 11 amino acids. dl1265 has a 39-bp deletion
between map units 0.172 and 0.179 and lacks the last 9 amino acids of the large-T
protein, although it has 4 new amino acids not normally present in the protein
(57).
The WT and mutant plasmids containing the large-T gene used for assaying
the large-T translational complementation phenotype of the VA-negative Ad
mutants have been described previously (53, 56, 57). These recombinant plas-
mids contain the entire SV40 genome in a pBR322 background, and the viral
large-T gene is expressed from the SV40 early promoter. The positions of the
mutations in the large-T gene of these plasmids are shown in Fig. 7. Both the WT
and mutants (except mutants 401/450, 451/500, and 601/650) are replication
defective because of a small deletion in the replication origin. Mutants 401/450,
451/500, and 601/650 contain only the SV40 early region and promoter-enhancer
in an ori1 background (30). Plasmid pR137 was constructed so that the initiator
AUG codon of the large-T gene was mutated into a chain terminator codon by
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using the PCR approach. Plasmid pR108 expresses only the SV40 small-t protein
(39).
Preparation of labeled, infected cell extracts. Cells in 35-mm-diameter dishes
were infected with the appropriate virus (SV40 or Ad) for 19 h at 10 PFU per
cell. Metabolic labeling with 100 mCi of [35S]methionine per ml was then per-
formed for 1 h in methionine-free DME. After two rinses in ice-cold phosphate-
buffered saline (PBS), the cells were lysed in 500 ml of ice-cold 13 radioimmu-
noprecipitation assay buffer (0.01 M Tris-HCl [pH 7.2], 0.15 M sodium chloride,
1% Triton X-100, 0.1% sodium dodecyl sulfate [SDS], 1% sodium deoxycholate,
5 mM EDTA, 0.2% azide, and 1 mM phenylmethylsulfonyl fluoride [PMSF]).
Lysates were spun at 30,000 3 g for 30 min at 48C, and the supernate was stored
at2208C until further use. Twenty microliters of the lysate was denatured in SDS
sample-loading buffer and analyzed by SDS–20% polyacrylamide gel electro-
phoresis (PAGE), when the whole-cell lysate was used to evaluate the phenotype
(17). Routinely, 150 to 200 ml of the lysate was used for the various immuno-
precipitations described below.
Immunoprecipitation of hexon, fiber, DBP, and large-T antigen. Lysates cor-
responding to 1.5 3 105 CV-1p cells were used for each immunoprecipitation,
and the number of cells was kept constant for comparison of the phenotypes. All
immunoprecipitation steps were carried out at 48C. The lysates were incubated
with the appropriate dilution of the respective antibody for 45 min and then
treated with 40 ml of a 10% suspension of Staphylococcus aureus cells for 15 min.
The immune complexes were then washed twice with solution I (100 mM Tris-
HCl [pH 8.8], containing 500 mM lithium chloride) and once with solution II
(fivefold dilution of solution I). Complexes were then denatured by boiling in
SDS sample buffer and analyzed on SDS–20% PAGE gels (17). Antibodies used
were 2Hx-2 for hexon (American Type Culture Collection), PAb419 for large-T
antigen (a kind gift of M. K. Rundell, Northwestern University), an anti-72-kDa
protein monoclonal antibody for single-stranded-DNA-binding protein (DBP),
and a polyclonal antifiber antibody for fiber (the last two were kind gifts of A.
Levine, Princeton University).
Transfection protocol. CV-1p cells were plated in 35-mm-diameter plates at an
appropriate density so that they were approximately 80% confluent about 24 h
later. Ten micrograms of plasmid DNAs containing WT or mutant large-T genes
was ethanol precipitated and resuspended in 250 ml of H2O and then mixed with
250 ml of 23 transfection buffer which contained 250 mM CaCl2; 50 mM BES
(N,N-bis[2-hydroxyethyl]-2-aminoethanesulfonic acid), pH 7.0; 280 mM NaCl;
and 1.5 mM Na2HPO4. The samples were incubated at room temperature for 20
to 30 min so that efficient precipitation could occur. The DNA-calcium phos-
phate precipitate was gently applied to the cells. The cells were incubated with
the DNA for 30 min at 378C in a 3% CO2 incubator and then fed with medium
that contained 10% fetal calf serum, 6.25 mM CaCl2, 1.25 mM BES, 0.0375 mM
Na2HPO4, and 7 mM NaCl and maintained at 3% CO2 for 18 to 20 h. The cells
were then treated with 20% glycerol for 3 min, washed twice with prewarmed
DME, refed with DME containing 10% fetal calf serum, and incubated for an
additional 40 h at 8% CO2. The cells were then either lysed or infected prior to
being labeled with [35S]methionine, as indicated in the figure legends. Because
the stabilities of the mutant large-T proteins varied considerably, the quantita-
tion of steady-state levels of the protein in the cells was considered more relevant
to our assay than was the determination of transfection efficiency. Large-T
antigen synthesized by various large-T plasmids was quantitated by Western blots
(immunoblots).
Complementation assays. CV-1p cells, in 35-mm-diameter dishes, were trans-
fected with plasmid DNAs containing WT or mutant large-T genes as described
above and then infected with sub720 at 10 PFU per cell for 19 h; the cells were
then labeled with [35S]methionine for 1 h. The cell lysates were prepared, and
synthesis of hexon was quantitated by immunoprecipitation with a monoclonal
antibody specific for hexon protein. The ability of the WT or mutant large-T
genes to complement the translational defect resulting from sub720 infections
was assessed by comparing the amounts of hexon synthesized in sub720-infected
cells in the presence and absence of large-T antigen.
Large-T Western blots. To determine the amounts of large-T antigen synthe-
sized from the transfected gene, large-T protein was quantitated by Western blot
analysis by using a portion of the cell lysates used for the immunoprecipitation of
hexon. Large-T antigen was immunoprecipitated from equal amounts of extracts
with the large-T-specific antibodies PAb901 and PAb902 (56). Antibody PAb902
recognizes all the large-T mutant proteins shown in Fig. 7, whereas antibody
PAb901 recognizes all but dl2459 and dl1265. The immunoprecipitated proteins
were separated on SDS–7.5% PAGE gels; the proteins were then transferred to
nitrocellulose filters, and the filters were blocked with 5% nonfat milk powder.
The filters were then probed with the antibodies PAb901 and PAb902. The
immunocomplexes were detected by hybridizing the filters with 125I-labeled anti-
mouse immunoglobulin G. After three washes in PBS–0.5% Tween, the filters
were autoradiographed.
Determination of p68 kinase activation levels. CV-1p cells were infected with
the various viruses for 20 h. Cells were rinsed once with phosphate-free DME
and labeled with 200 mCi of 32Pi per ml for the last 8 h of the infection. All
further operations were performed at 48C. After being rinsed with PBS, the cells
were lysed in a buffer containing 1% Triton X-100, 50 mM KCl, 10 mM Tris-HCl
(pH 7.5), 1 mM dithiothreitol, 2 mM MgCl2, 0.2 mM PMSF, and 100 mg of
aprotinin per ml as described elsewhere (29). Extracts were clarified by centrif-
ugation at 30,000 3 g for 30 min at 48C. The extracts were then diluted with 500
ml of buffer I (20 mM Tris-HCl [pH 7.5], 50 mM KCl, 0.4 M NaCl, 1% Triton
X-100, 1 mM EDTA, 10 mg of aprotinin per ml, 1 mM dithiothreitol, 0.2 mM
PMSF, and 20% glycerol) and incubated for 1 h with 3 ml of a polyclonal
antibody raised in rabbits against baculovirus-expressed human PKR, which is
capable of recognizing monkey and mouse PKR as well (4). The lysates were
then incubated for an additional 1 h with 75 ml of a 10% suspension of protein
A-agarose (Boehringer Mannheim). The immune complexes were pelleted and
washed four times in buffer I and three times in buffer II (10 mM Tris-HCl [pH
7.5], 100 mM KCl, 0.1 mM EDTA, 10 mg of aprotinin per ml, and 20% glycerol).
The immunoprecipitated polypeptides were analyzed by SDS-PAGE and pro-
cessed for autoradiography.
Primer extension analysis. CV-1p cells were transfected as described above,
total cellular RNA was prepared by the guanidine isothiocyanate method, and
poly(A)1 RNA was then separated on oligo(dT) columns as described elsewhere
(43). Equal quantities of RNA (approximately 1 mg) were used for the large-T
primer extension; approximately 0.1 mg was used for the b-actin primer extension
to normalize the mRNAs. Primer extensions were performed as described by
Ausubel et al. (3), except for the following details. Primers were end labeled at
the 59 end, 105 cpm was used per extension reaction, and the annealing was
carried out overnight at 308C. After precipitation of the nucleic acids, the an-
nealed primer was extended for 3 h with 40 U of avian myeloblastosis virus
reverse transcriptase (Promega) and the extended products were analyzed on 6%
DNA-sequencing gels. The large-T primer extends from positions SV4526 to
SV4557 (9), and the b-actin primer used for quantitative normalization of the
RNA is complementary to positions 178 to 1105 of the human b-actin gene
(numbering is in relation to the cap site of actin mRNA).
OA experiments. CV-1p or COS cells were infected with the respective viruses
at 10 PFU per cell. After incubation for 1 h to allow virus adsorption, the cells
were fed with DME containing 2% calf serum and the appropriate amount of
okadaic acid (OA) (a kind gift of Mark Johnson, Northwestern University). The
infection was allowed to proceed for 20 h. The cells were labeled during the last
1 h of infection and lysed, as described above. Hexon immunoprecipitations were
then performed on the lysates, as described above.
RESULTS
SV40 large-T protein is responsible for the rescue of the
translational defect resulting from infection with an Ad mu-
tant lacking the VAI RNA gene. Ad mutants with the VAI
RNA gene deleted show a dramatic reduction in viral polypep-
tide synthesis at late times after infection (46, 55). We previ-
ously reported that monkey cells infected with VAI-negative
mutants also show this phenotype and that this translational
defect can be rescued by coinfecting cells with SV40. Our
studies have indicated that this complementation occurs at the
level of translation (51).
In order to determine whether the translational defect man-
ifested by monkey cells infected with VA-negative Ad mutants
is similar to that of human cells, we analyzed by quantitative
immunoprecipitation the levels of three Ad proteins, hexon,
fiber, and DBP, in CV-1p cells infected with dl704 or sub720
(Fig. 1). Hexon and fiber are synthesized abundantly at late
times postinfection from the major late promoter. DBP is
transcribed from the E2 promoter at both early and late times.
The supernatants from the first round of DBP immunoprecipi-
tations were reimmunoprecipitated (see Fig. 1 legend) to en-
able a more precise quantitation of the translational defect
(Fig. 1, lanes 13 to 16). Synthesis of all three viral proteins
tested was reduced in the sub720-infected cells (Fig. 1, lanes 3,
7, and 15) compared with the WT Ad-infected cells (lanes 2, 6,
and 14). Thus, our studies show that the translational defect in
CV-1p cells that results from infection of a VA-negative Ad
mutant is extended to both early and late viral proteins at late
times after infection, indicating that the translational defect
caused by the deletion of the VAI gene in CV-1p cells is
identical to that observed to occur in human cells. Further,
coinfection with SV40 restores the translation of all three Ad
proteins to WT levels (Fig. 1, compare lanes 4, 8, and 16 with
lanes 2, 6, and 14, respectively). However, the identity of the
SV40 gene product responsible for this complementation and
the mechanism by which this complementation occurs have not
been established.
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At early times after infection, SV40 encodes three gene
products. These are large-T antigen, small-t antigen, and the
recently identified 17kT (58), which arise from a single primary
transcript as a result of differential splicing. Three capsid pro-
teins and agnoprotein are encoded by the late region. To
determine the SV40 gene products responsible for the comple-
mentation, we have developed a combined transient transfec-
tion and virus infection assay. In this assay, CV-1p cells were
first transfected with either a plasmid containing the entire
replication-defective SV40 genome or a plasmid expressing
only the SV40 small-t antigen. After 60 h, the cells were in-
fected with the translationally defective Ad mutant sub720,
which had the VAI and VAII RNA genes deleted (6, 17).
Rescue of the translational defect resulting from sub720 infec-
tion by SV40 genes was assayed by quantitative immunopre-
cipitation of hexon, a major coat protein of Ad. Mock trans-
fection followed by WT Ad or sub720 infection were also
carried out in parallel as controls. As expected, in control
experiments in which cells were infected with phenotypically
WT Ad variant dl704, large amounts of hexon protein were
detectable (Fig. 2A, lane 2), whereas in cells infected with the
defective mutant sub720, hexon protein was undetectable (lane
3). Plasmid p6-1, which contains the entire SV40 chromosome,
was able to rescue the decreased protein synthesis of sub720 to
WT levels (Fig. 2A, compare lane 4 with lane 2). It is note-
worthy that in terms of the levels of hexon protein detected,
the transfection experiment (Fig. 2A, lane 4) parallels the
infection experiment (lane 2). Considering that only 20 to 30%
of the cells are transfected, perhaps the introduction of a large
number of plasmid copies into each cell of the transfected
population may account for the WT (Fig. 2A, lane 4) or more-
than-WT levels (Fig. 2D, lane 2) of hexon detected. A plasmid
which expressed only the small-t gene (pR108) did not com-
plement the VAI RNA function (Fig. 2A, compare lane 5 with
lanes 2 and 4).
FIG. 1. Synthesis of both early and late viral polypeptides is reduced in
CV-1p cells infected with the VA-negative Ad mutant sub720. CV-1p cells were
infected with the indicated viruses (Ad variants dl704 and sub720 are phenotyp-
ically WT and VAI2 VAII2, respectively) at 10 PFU per cell for 20 h. The cells
were labeled with [35S]methionine during the last hour of infection, harvested,
and lysed. The labeled viral polypeptides were immunoprecipitated and analyzed
on SDS–20% PAGE gels. The antibodies used were 2Hx-2 for hexon (A), an
anti-72-KDa protein monoclonal antibody for DBP (C), and a polyclonal anti-
body for fiber (B) (the last two were kindly donated by A. Levine, Princeton
University). The arrowheads indicate the positions of the immunoprecipitated
proteins. Because the bands in lanes 10 to 12 in panel C were too intense for
quantitative comparison, the supernatants from the first round of DBP immu-
noprecipitation were reimmunoprecipitated (lanes 13 to 16). DBP bands in lanes
14 to 16 were quantitated by laser densitometry. Radioactive bands for panels A
and B were compared by visual inspection.
FIG. 2. The large-T protein of SV40 is responsible for the complementation
of the Ad VA RNA-negative mutant phenotype. (A) Transfection of the WT
SV40 large-T gene complements the sub720 (VAI2 VAII2) phenotype. CV-1p
cells were either mock infected (lane 1) or infected with a phenotypically WT Ad
(dl704; lane 2) or sub720 (lane 3) at 10 PFU per cell for 20 h. Cells were labeled
with [35S]methionine for the last hour of infection, and the amount of hexon
polypeptide was quantitated by immunoprecipitation. In the experiments shown
in lanes 4 and 5, cells were transfected with 10 mg of p6-1, which contains the WT
large-T gene (lane 4), or pR108, which contains the small-t gene (lane 5), for 60
h and then infected with sub720. Cells were labeled with [35S]methionine, and
hexon polypeptide (arrowhead) was quantitated as previously described. The
identity of the band migrating at a position above the hexon polypeptide is not
known. (B) Quantitation of the large-T-specific mRNAs produced in CV-1p cells
transfected with p6-1, which contains a WT large-T gene, or pR137, which
contains a mutant large-T gene with a mutation in the AUG codon (mut AUG).
CV-1p cells (100-mm-diameter dishes) were transfected with 10 mg of p6-1 or
pR137, and poly(A)1 RNA was isolated and quantitated by a primer extension
approach as described in Materials and Methods. The positions of DNA markers
are indicated on the left. The arrowhead shows the primer-extended product.
The nucleotide sequence of the oligonucleotide used for priming the PCR
synthesis in the construction of pR137 is 59-GCA AAA AGC TTT GCA AAG
AGC GGA TAA AGT TT-39. The nucleotides underlined represent mutations
with one substitution (G) and one insertion (C). The WT sequence in this region
is 59-GCA AAA AGC TTT GCA AAG ATG GAT AAA GTT T-39. The
double-underlined sequence is the initiator codon of the large-T gene. M, mark-
ers. (C) Quantitation of the b-actin mRNA. b-Actin mRNA was quantitated
from RNA samples used in the experiment shown in panel B under conditions
the same as those used for panel B with a primer which spans b-actin mRNA
sequences from positions 178 to 1105 (relative to the mRNA cap site). The
arrowhead shows the primer-extended product. (D) Large-T mRNA alone does
not complement the VA RNA-negative phenotype of sub720. Cells were trans-
fected with either pR137, in which the AUG codon is mutated, or p6-1, contain-
ing the WT large-T gene, for 60 h and then infected with sub720 for 20 h. Hexon
immunoprecipitations were then performed to quantitate the extent of comple-
mentation by the two plasmids. Lanes 3, 4, and 5 represent virus infection
experiments similar to those shown in lanes 1, 2, and 3 of panel A. The arrow-
head shows the hexon protein.
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Additional evidence that the small-t antigen did not play a
role in causing this phenotype came from virus infection ex-
periments, as shown in Fig. 3, using the SV40 mutant dl888,
which does not produce small-t mRNA. CV-1p cells were coin-
fected with SV40 and Ad viruses, and levels of Ad protein
synthesized were visualized by radiolabeling in vivo followed by
analysis on denaturing gels. As expected, the monkey cells
infected with either sub722 (lacking the VAI gene) or sub720
(lacking both the VA genes) displayed the translational defect
characteristic of the VA-negative mutants (Fig. 3, compare
lanes 7 and 8 with lane 6). This phenotype is identical to that
seen with human 293 cells (Fig. 3, lanes 1 to 4). WT SV40
restored protein synthesis in CV-1p cells infected with either
sub722 or sub720 (compare lanes 12 and 13 of Fig. 3B with
lanes 7 and 8 of Fig. 3A). Consistent with the results of the
transfection experiments described above, dl888 also comple-
mented the translational defect (compare lanes 15 and 16 of
Fig. 3B with lanes 7 and 8 of Fig. 3A), albeit slightly less
effectively than did WT SV40 (Fig. 3B, compare lanes 15 and
16 with lanes 12 and 13). However, dl888 synthesizes lesser
amounts of large-T antigen than does WT SV40 (Fig. 3C),
presumably because of lower replication rates. This may ac-
count for the slightly reduced complementation ability of this
mutant. Thus, we conclude that dl888 can correct the VA-
negative translational defect in the absence of small-t antigen.
The role of the recently described 17kT protein, which is de-
rived from the N-terminal region of large-T antigen as a result
of alternative splicing (58), has not been evaluated in this
study. However, analysis of large-T mutants in this study (see
below) suggests that the 17kT protein by itself cannot rescue
the translational defect. In addition, we have also found that
the large-T gene cloned in a cytomegalovirus expression vector
is capable of complementing the VA-negative phenotype in
transient assays, ruling out the involvement of late gene prod-
ucts of SV40 in this process (data not shown). Together, these
results indicate that the complementation function of SV40 is
encoded in the large-T antigen gene.
Because VA RNAs directly affect translation by binding to
and inactivating the double-stranded-RNA-activated protein
kinase PKR (18, 29), it seemed possible that the rescue of the
translational defect by the SV40 large-T antigen might be me-
diated by the mRNA that encodes the large-T antigen, rather
than by the protein. By using the PCR approach, a mutant
large-T plasmid (pR137) was constructed in which a single
base was substituted at SV5166 and one base was added after
SV5166 (numbering is based on the SV40 numbering system
[9]). As a result, the translation initiator codon of the gene was
mutated, resulting in the frameshift of the reading frame of the
large-T protein by one base (see Fig. 2 legend for the nucle-
otide sequence of the mutation). This mutant is not expected
to synthesize the large-T protein. CV-1p cells were transfected
with pR137, and the capacity for phenotypic complementation
by the mutant large-T gene was quantitated as described
above. As shown in Fig. 2D, the mutant large-T gene of pR137
did not complement the VA RNA-specific defect in comple-
mentation assays (Fig. 2D, compare lane 1 with lane 2). To
ensure that cells transfected with pR137 contained large-T
mRNAs comparable to those of the WT control, total RNAs
were isolated from one-half of the cells used in the experiments
shown in Fig. 2D and the large-T mRNAs were quantitated by
a primer extension approach. Poly(A)1 RNAs were prepared
from the transfected cells and annealed to a 59-end-labeled
primer spanning positions SV4526 to SV4557. The primers
were then extended with reverse transcriptase, and the ex-
tended products were analyzed on 6% DNA sequencing gels.
Actin mRNAs were also quantitated by using appropriate
primers (Fig. 2C). Approximately equal amounts of a cDNA
product (;360 nucleotides long) were detected from cells
transfected with the WT and pR137 plasmids, indicating that
the levels of mRNAs synthesized from the WT and the mutant
large-T genes were comparable in CV-1p cells at 60 h post-
transfection (Fig. 2B, compare lanes 3 and 4). As expected, we
could not detect any large-T protein synthesized from this
mutant gene (data not shown). Thus, we conclude that the
large-T mRNA by itself does not contribute to the comple-
mentation of the translational defect of the Ad mutant lacking
the VA RNA genes.
SV40 large-T antigen does not block the activation of PKR
in monkey cells infected with VA-negative Ad mutant. Previous
studies have shown that when human cells are infected with a
VA-negative Ad mutant, PKR is highly phosphorylated (and
thereby activated) but the levels of this protein remain unal-
tered (29). The activation of PKR results in the phosphoryla-
tion of the a subunit of eIF-2. Because the activation of PKR
is known to play a pivotal role in the manifestation of the VA
RNA-negative phenotype of Ad, it seemed possible that the
SV40 large-T protein may rescue the translational defect that
ensues after infection with sub720 by blocking the activation of
PKR, a mechanism similar to that of VA RNA (29, 46, 50).
Therefore, we compared the levels of phosphorylated PKR in
sub720-infected CV-1p cells in the absence (Fig. 4A, 720 lane)
and presence (7201SV40 lane) of large-T antigen. Parallel
control experiments in which levels of phosphorylated PKR
were estimated for CV-1p cells infected with SV40 or the
phenotypically WT Ad variant dl704 were also carried out. To
compare these results with those obtained previously with hu-
man cells (29), the levels of phosphorylated PKR were also
determined for human 293 cells infected with either dl704 or
sub720. Cells were infected with various viruses and labeled
with 32Pi for the last 8 h of the 20-h infection, and PKR was
FIG. 3. The SV40 small-t gene is not required for the manifestation of the
complementation phenotype. (A) 293 and CV-1p cells were either mock infected
or infected with either WT Ad (dl704) or the VA-negative mutants (sub722
[VAI2 VAII1] and sub720 [VAI2 VAII2]) at 10 PFU per cell. Total proteins
synthesized at 20 h postinfection were analyzed on denaturing gels as described
in Materials and Methods. Lanes 9 and 10 show proteins synthesized during a
single infection with WT SV40 and dl888 (a small-t-negative mutant), respec-
tively. II and 100K represent the two major late Ad proteins hexon and the
100-kDa protein, respectively. (B) Complementation of the VA-negative phe-
notype of Ad by coinfection with WT SV40 or dl888. CV-1p cells were coinfected
with the indicated Ad and SV40 mutants at 10 PFU per cell each for 20 h, and
protein profiles were analyzed as described in Materials and Methods. (C)
Quantitation of the amount of large-T antigen synthesized in WT SV40 and
dl888 infections. CV-1p cells were infected with WT SV40 or dl888 at 10 PFU per
cell each for 20 h, labeled with [35S]methionine during the last hour of infection,
harvested, and lysed. Large-T (T) and small-t (t) antigens were immunoprecipi-
tated with a polyclonal antiserum raised against the SV40 tumor antigens in
hamsters. Immunoprecipitations were performed in the same lysates that were
used for panel A, lanes 9 and 10.
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immunoprecipitated by using a polyclonal antiserum raised
against human PKR. The phosphorylated proteins were then
analyzed by SDS-PAGE. Figure 4 shows these results. Note
that the immunoprecipitates in the two panels of Fig. 4 were
analyzed in two different gels under different electrophoretic
conditions (see Fig. 4 legend). In agreement with previous
results, 293 cells infected with sub720 showed a large increase
in the phosphorylation of PKR (Fig. 4B). Consistent with this,
CV-1p cells infected with sub720 also showed a large increase
in the levels of phosphorylated PKR (Fig. 4A). Thus, this
manifestation of the VA-negative phenotype in monkey cells is
consistent with that seen to occur in human cells (37, 54) (Fig.
4B). Contrary to expectations, a large increase in the levels of
phosphorylated PKR was also observed with monkey cells
coinfected with sub720 and WT SV40 (Fig. 4A). The levels of
phosphorylated PKR in these cells were comparable to those
in cells infected with sub720, indicating that the large-T antigen
did not block the activation of PKR. These results were also
substantiated in in vitro experiments. A partially purified PKR
preparation was preincubated with purified large-T antigen in
vitro and then incubated with double-stranded RNA. Control
experiments without large-T antigen and with preincubation
with VAI RNA were also carried out in parallel. Large-T
antigen did not block the activation of PKR in vitro, whereas
VAI RNA blocked the activation of PKR effectively (data not
shown). We conclude that SV40 large-T antigen does not res-
cue the translational defect of sub720 by blocking the activa-
tion of PKR. The mechanism by which SV40 large-T antigen
rescues the translational defect appears to be quite distinct
from the one employed by VAI RNA in that it acts down-
stream of the PKR activation step.
An important question is whether, in monkey cells coin-
fected with SV40 and sub720, eIF-2 is phosphorylated to the
same extent as it is in cells infected with sub720 alone. In
human cells infected with VA-negative Ad mutants, eIF-2 is
phosphorylated to levels much higher than those in cells in-
fected with WT Ad as a consequence of PKR activation (46,
50). This in turn halts protein synthesis. To date, our repeated
attempts to determine the phosphorylation status of eIF-2 in
monkey cells infected with sub720 or sub720 and WT SV40
have been unsuccessful (see Discussion). One mechanism by
which SV40 large-T antigen may rescue the translational de-
fect despite a large increase in the phosphorylation of PKR
may be by dephosphorylation of eIF-2. Because the levels of
activation of PKR of the sub720 infection were unaltered dur-
ing an SV40 WT coinfection, it was possible that the SV40
large-T antigen was acting through a phosphatase function that
was directed downstream of the p68 kinase step in the protein
synthesis initiation pathway, presumably by dephosphorylation
of eIF-2. It has been shown that protein phosphatase 2A
(PP2A), a cellular phosphatase, has the capacity to dephos-
phorylate the a subunit of eIF-2 at Ser-51 in in vitro experi-
ments (40).
Phosphorylation of Ser-51 of eIF-2a results in the cessation
of protein synthesis. We used OA, an inhibitor of PP2A (11),
to determine whether PP2A may be involved in the large-T-
mediated rescue of the translational defect. Results of exper-
iments in which we treated CV-1p cells coinfected with SV40
and sub720 were difficult to interpret because we found that
OA, at low concentrations, significantly inhibited replication of
SV40, consistent with published reports (33) (data not shown).
As a result, large-T antigen accumulated to much reduced
levels which were not adequate for complementation (data not
shown). Therefore, we studied the effect of OA using COS
cells, a CV-1 cell line which constitutively expresses the WT
large-T antigen (19). We previously showed that COS cells
infected with sub720 do not show the translational defect phe-
notype (51). COS cells were infected with sub720 or WT Ad
and then treated with increasing concentrations of OA. Cells
were radiolabeled with [35S]methionine for 1 h at 19 h postin-
fection and then lysed, and hexon was immunoprecipitated as
described above. Figure 5A shows that at a concentration of 30
ng/ml, there was significantly reduced synthesis of hexon in
COS cells infected with sub720 in comparison with synthesis in
untreated cells (compare lane 2 with lane 5), indicating that the
function provided by the large-T antigen is inhibited by OA.
FIG. 4. In vivo phosphorylation of PKR in infected monkey (A) and human
(B) cells. CV-1p and 293 cells were infected with the indicated viruses at 25 PFU
per cell for 20 h and labeled with 32Pi for the last 8 h of the infection. PKR was
immunoprecipitated from the extracts prepared from 5 3 106 cells by using a
polyclonal antiserum raised against human PKR. PKR from CV-1p cells (A) was
immunoprecipitated by using a polyclonal antibody raised against baculovirus-
expressed human PKR which also recognizes monkey and mouse PKRs (4). PKR
from 293 cells (B) was immunoprecipitated by using a polyclonal antiserum
raised against bacterially expressed human PKR, a kind gift of M. B. Mathews,
Cold Spring Harbor Laboratory. The immunoprecipitated proteins were then
analyzed on SDS-PAGE gels. The immunoprecipitates shown in panel A were
run on SDS–12.5% PAGE gels, whereas those shown in panel B were run on
SDS–20% PAGE gels. However, it is to be noted that in both instances, the
immunoprecipitated protein migrated as expected at about 68 kDa. Arrowheads
indicate the position of PKR. The positions of the protein molecular weight
markers are indicated on the left (numbers are in thousands).
FIG. 5. OA reverses the complementation phenotype of the SV40 large-T
antigen in COS cells. (A) Complementation of the VA-negative mutant pheno-
type by the large-T antigen in COS cells. COS cells were infected with dl704 or
sub720 and treated with OA (0 to 30 ng/ml) as described in Materials and
Methods. Infection was allowed to proceed for 20 h. The cells were labeled with
[35S]methionine during the last hour of infection, harvested, and lysed. The
hexon was immunoprecipitated (lanes 1 to 9) as described in Materials and
Methods. 1, virus present; 2, virus absent. (B) Quantitation of the large-T
antigen in COS cells treated with OA. Large-T antigen in the left and right lanes
was immunoprecipitated from the same extracts used for lanes 6 and 9, respec-
tively, of the gel shown in panel A. T, large-T antigen.
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Immunoprecipitations of large-T antigen performed in parallel
with the same extracts did not show any decrease in large-T
levels (Fig. 5B). Thus, the reduced protein synthesis in sub720-
infected cells in the presence of OA is not the result of reduced
synthesis of large-T antigen. OA did not affect WT Ad protein
synthesis because the amounts of hexon protein synthesized in
the presence of 30 ng of OA per ml were comparable to those
synthesized without OA (Fig. 5A, compare lane 9 with lane 6).
This concentration of OA was sufficient to inhibit the large-T-
mediated complementation effect (Fig. 5A, compare lane 5
with lane 2). These results also indicate that the reduced pro-
tein synthesis in sub720-infected cells in the presence of OA is
not the result of inefficient entry of the mutant virus into the
cell. It is also interesting that levels of hexon synthesized by
dl704 are slightly higher than those synthesized by sub720.
Perhaps SV40 large-T antigen does not substitute completely
for the VAI function. In summary, these results suggest that,
perhaps, a phosphatase may be involved in large-T-mediated
complementation of VAI RNA function.
Identification of a domain in large-T antigen that is respon-
sible for the complementation function. The large-T antigen is
a 90-kDa protein which is essential for the successful comple-
tion of the virus life cycle. At least 15 functions and activities
have been assigned to or associated with the large-T antigen,
and these activities are distributed at different locations in the
molecule. Some of these functions are targeted toward regu-
lating the life cycle of the virus, while others regulate the
cellular events that transpire in the host cell after infection
(reviewed in reference 16). To determine the domain in the
large-T antigen that is responsible for the complementation
function, we analyzed a number of previously characterized
large-T mutants in the transient transfection assay described
above. The large-T gene in all these mutants was expressed
from its own promoter. CV-1p cells were transfected with WT
or mutant large-T plasmids and after 60 h were infected with
the VA-negative mutant, sub720. Twenty hours after infection,
synthesis of hexon polypeptide was quantitated by immunopre-
cipitation of radiolabeled proteins. Because the stabilities of
the mutant large-T proteins vary considerably, the steady-state
levels of large-T protein synthesized from the transfected gene
in the same extract were quantitated by Western blot, as de-
scribed in Materials and Methods. Quantitation of steady-state
levels of the large-T protein in the cell was considered more
relevant for our assay than was the determination of transfec-
tion efficiency because the capacities of the large-T mutants to
complement the translational defect of sub720 correlate with
the steady-state levels of large-T antigen. A total of 26 mutants
with mutations in the large-T gene were assayed for their
capacity to complement the VA RNA-negative Ad phenotype,
and only those mutants that produced detectable amounts of
stable large-T protein were used to evaluate complementation
ability. Complementation assays were carried out at least three
times with independently grown plasmid preparations, and
similar results were obtained. The results of one such experi-
ment are shown in Fig. 6. The large-T mutants used in this
study and their capacities to complement the translational de-
fect are schematically shown in Fig. 7.
It has been reported that the SV40 large-T antigen provides
a function which allows efficient late protein synthesis in Ad-
infected monkey cells. This phenomenon, referred to as the Ad
helper function of SV40, is known to reside in the extreme
C-terminal region of the large-T antigen (14, 35, 38). The
helper function has proven to be very complicated and is
thought to act at multiple levels, including splicing, nucleocy-
toplasmic transport of viral messages, and transcription rate
and transcriptional termination (references 27 and 31 and ref-
erences cited in those papers). It seemed possible that the
translation complementation phenotype of the large-T antigen
for Ad mutants in monkey cells was yet another facet of this
complex function. To resolve this, three large-T mutants,
FIG. 6. Localization of the domain of large-T antigen which is important for the complementation function. (A) Ability of the various SV40 mutants to complement
the VA RNA-negative phenotype of Ad. CV-1p cells were transfected with 10 mg of the indicated mutants with mutations in the large-T gene. Sixty hours after
transfection, the cells were infected with sub720 (1) or left without sub720 infection (2) as indicated. Infection was allowed to proceed for 20 h. During the last hour
of infection, the cells were labeled with [35S]methionine, harvested, and lysed and the hexon polypeptide (arrowhead) was immunoprecipitated from an equal number
of cells. Lane 1 shows the amount of hexon synthesized in a WT Ad infection, and lane 2 shows the amount synthesized in a sub720 infection. See Fig. 7 for the positions
of the mutations in the large-T gene. (B) The steady-state levels of the large-T protein were determined by using the same lysates from which the hexon was quantitated
in the experiment shown in panel A. A Western blot analysis was performed as described in Materials and Methods. The position of the large-T protein is indicated
by small arrowheads. Each mutant was assayed at least three times. One representative experiment is shown.
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dl1263, dl1265, and dl2459, which are defective for the Ad
helper function (21), were assayed in the transient assays de-
scribed above. Of these three mutants, dl2459 was severely
defective for the helper function, whereas dl1263 and dl1265
retained 33 and 8% of WT helper activity, respectively (14, 21).
As shown in Fig. 6A, all three mutants complemented the VA
RNA-related translational defect significantly and the levels of
complementation among the three mutants were comparable.
The complementation capacities of dl1263 and dl1265 were
also assayed by coinfecting mutant viruses which harbored
these mutant genes with sub720 and analyzing viral polypep-
tides as previously described (51). These results, shown in Fig.
8, confirmed the data obtained in the transient assays. The
decreased protein synthesis in CV-1p cells infected with VA-
negative Ad (Fig. 8A, compare the 722 and 720 lanes with the
704 lane) was restored to normal levels by coinfection with WT
SV40 (Fig. 8B, WT lanes). Both dl1263 and dl1265 efficiently
corrected the VA-negative defect (Fig. 8B, compare 1265 and
1263 lanes with the WT lanes). Complementation assays with
dl2459 could not be carried out at the virus level, as stocks of
sufficiently high titer could not be obtained for this mutant. In
addition, we could not see any complementation when large-T
plasmid was replaced with an expression plasmid which ex-
pressed a mutant form of the 72-kDa DBP (Ad2hr404) (data
not shown). Mutant Ad2hr404 has been shown to overcome
the block to growth of Ad in monkey cells (32). Together, these
results show that the SV40 large-T protein is capable of com-
plementing the VAI function independently of the Ad helper
function.
Large-T antigen is known to encode an ATPase function
which resides in the C-terminal half of the protein between
amino acids 415 and 630 (12). Mutants dl2827 and dl2432 lack
this function (12). In our transient assays, both mutants syn-
thesized significant quantities of large-T antigen (Fig. 6B, lanes
6 and 7) and complemented the VA RNA function signifi-
cantly (Fig. 6A, lanes 7 and 8), indicating that the large-T-
mediated rescue of the translational defect is independent of
the ATPase function. SV40 large-T antigen has been shown to
bind to tumor suppressor gene product p53, and the region
that is essential for this binding has been mapped to the do-
main between amino acids 272 and 517 (reviewed in reference
16). Mutant 402DH is defective for large-T antigen’s stable
association with p53 (50a). In transient assays, this mutant
FIG. 7. Diagrammatic representation of the various large-T mutant genes
employed in determining the complementation domain and their capacity to
rescue the translational defect specific for the VA-negative Ad mutant. The WT
large-T protein has 708 amino acids. Black boxes denote deletions between the
indicated amino acid positions in the various mutants. Insertion mutations (Ins)
are shown by vertical lines. dl1265 lacks the last 9 amino acids of the large-T
protein but has 4 new amino acids not normally present in the protein (57). Not
shown is mutant 1209, which lacks the entire large-T coding region (14). Because
the stabilities of the mutant large-T proteins vary considerably, the steady-state
level of large-T protein synthesized from the transfected gene was quantitated by
Western blotting. A mutant which showed detectable levels of large-T antigen in
the Western analysis was scored as either positive or negative depending on the
detection of the hexon protein (see Fig. 6).
FIG. 8. The helper-defective SV40 mutants complement the Ad VA-negative defect as efficiently as WT SV40. (A) Translation defect of the VA RNA-negative
mutants in 293 and CV-1p cells. 293 and CV-1p cells were infected with either WT Ad (dl704) or the VA-negative mutants (sub722 and sub720) at 10 PFU per cell.
Viral polypeptides synthesized 20 h postinfection were analyzed on denaturing gels. (B) Complementation of the VA-negative phenotype of Ad by a coinfection with
WT SV40, dl1263, or dl1265. CV-1p cells were coinfected with the indicated Ad and SV40 mutants at 10 PFU per cell each for 20 h, and the viral polypeptides were
analyzed as described in Materials and Methods. II and 100K represent hexon and the 100-kDa protein, respectively.
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synthesized barely detectable amounts of large-T antigen (Fig.
6B, lane 18); however, hexon protein was detected in the
complementation assays (Fig. 6A, lane 24). These results sug-
gest that the translational complementation function is inde-
pendent of large-T antigen’s association with p53. Several mu-
tants with deletion, substitution, and insertion mutations in the
N-terminal half of the second exon region were also found to
complement the VAI RNA function in our transient assays.
These include two insertion mutants, 2815 and 2817 (Fig. 6A,
lanes 11 and 10, respectively), which contain in-frame inser-
tions after amino acids 168 and 219, respectively, and a dele-
tion mutant (dl2411) in which amino acids 142 to 147 are
deleted (Fig. 6A, lane 16). Two substitution mutants, T22 and
C8A, in which histidine at position 203 and lysine at position
224 are substituted by glutamine and glutamic acid, respec-
tively, also complemented the VAI RNA function (Fig. 6A,
lanes 23 and 22, respectively). All these mutants synthesized
significant amounts of hexon (Fig. 6A).
Of all the mutants tested, mutants dl601/650, dl401/450, and
dl451/500, which contain deletions of amino acids between
positions 601 and 650, 401 and 450, and 451 and 500, respec-
tively, were found to be defective for the complementation
function (Fig. 6A, lanes 12, 13, and 14, respectively). These
mutants did synthesize detectable amounts of large-T antigen,
as evidenced by Western blot analysis (Fig. 6B, lanes 11, 12,
and 13). Failure of these mutants to complement the transla-
tional defect of sub720 is not the result of insufficient quantities
of large-T antigen because mutants dl1263 and dl2459 also
accumulated comparable amounts of large-T antigen under
identical conditions (Fig. 6B, compare lanes 3 and 5 with lanes
11, 12, and 13); nevertheless, mutants dl1263 and dl2459 com-
plemented the VAI RNA function to a significant level (Fig.
6A, compare lanes 4 and 6 with lanes 12, 13, and 14). Similarly,
mutant 402DH synthesized barely detectable amounts of
large-T antigen (Fig. 6B, lane 18) yet complemented the trans-
lational defect of sub720 to a detectable level (Fig. 6A, lane
24). Thus, we conclude that a domain between amino acids 401
and 650 is important for the translational complementation
function.
DISCUSSION
The cellular defense mechanisms that block a successful
virus infection usually center around the posttranscriptional
steps of the control of gene expression and are mediated in
several instances by PKR. Viruses have developed molecular
mechanisms which make it possible for them to circumvent the
host-cell-mediated block to their successful replication (re-
viewed in references 28, 36, and 44). The VA RNAs of Ad have
evolved as the viral mechanism that circumvents the host-cell-
mediated block during Ad infection (reviewed in references 37,
47, and 54). Our previously published results (51) and the
present studies show that mutants of Ad which lack VA RNAs
manifest the translational-defect phenotype in monkey cells, a
phenomenon identical to that observed for human cells. In
human cells, PKR that is activated as a consequence of infec-
tion by a VAI-negative virus (sub720 in this case) will phos-
phorylate eIF-2, which then will bind to and trap the guanine
nucleotide exchange factor GEF that is present in limiting
amounts. As a consequence, initiation of protein synthesis is
blocked (46, 50). In CV-1p cells infected with a VA-negative
mutant, both early and late Ad polypeptides are synthesized at
much reduced levels, indicating that the phenotype that results
from the deletion of the VAI gene from Ad is identical in both
human and monkey cells. This translational defect is reversed
when the cells are coinfected with WT SV40 and the pheno-
typic rescue occurs at the level of translation (51). In this study,
we have attempted to address two important questions related
to this translational complementation phenomenon, namely,
the mechanism by which SV40 complements the Ad VA RNA
function and the identification of the SV40 gene product re-
sponsible for this complementation.
In this investigation, we successfully employed a combina-
tion of transient transfection and a VA-negative virus infection
assay to study the complementation. Using these assays, we
have shown that the SV40 large-T gene product is responsible
for this complementation and that this complementation oc-
curs at the level of the protein. No detectable complementa-
tion was observed when plasmid pR137, in which the AUG of
the large-T open reading frame was mutated into a chain
termination codon, was used in the complementation assay.
Unlike Ad, SV40 does not encode an RNA polymerase III
gene product. However, SV40 has been reported to synthesize
a low-molecular-weight RNA, designated SAS-RNA, which is
believed to be a cleavage product of late transcripts (2). Be-
cause a plasmid which synthesizes only large-T antigen can
complement the VAI RNA function, and also because cells
transfected with pR137 contain amounts of large-T (and
small-t) mRNA comparable to those in cells transfected with
the WT plasmid, we can rule out the possibility that the SAS-
RNA or the mRNAs that encode the two early gene products
are responsible for this complementation. Cloned cDNA that
encodes WT large-T antigen can complement the VA-negative
defect as well as the large-T antigen synthesized in SV40 in-
fection can, indicating that this transient assay can be used to
study the domain in the large-T protein responsible for
complementation (see below). In our studies, a plasmid that
expresses only small-t antigen did not complement, suggesting
that this function does not overlap with those described for
small-t antigen.
As predicted, in CV-1p cells infected with the VA-negative
mutant sub720, PKR is phosphorylated to high levels, a result
that is consistent with its phenotype in human cells. The most
surprising observation, however, is that in CV-1p cells coin-
fected with sub720 andWT SV40, PKR is activated to the same
levels as in cells infected with sub720 alone. This indicates that
the translational rescue does not involve the prevention of
activation of PKR but functions at a step downstream of it.
This raises the important question of whether eIF-2 is phos-
phorylated to the same levels in cells infected with sub720 and
in cells coinfected with sub720 and WT SV40. Our numerous
attempts to determine the levels of phosphorylated eIF-2 in
monkey cells infected with sub720 have not been successful.
We used an isoelectric focusing immunoassay (48) and two-
dimensional PAGE followed by immunoblotting (24) to eval-
uate the phosphorylation status of eIF-2a in mock- and
sub720-infected CV-1p cells. Although we could detect eIF-2a
in these assays, we could not separate the phosphorylated and
unphosphorylated forms of the protein. Our attempts to mon-
itor the levels of eIF-2a phosphorylation by direct immuno-
precipitation from in vivo 32P-labeled CV-1p cell lysates using
a polyclonal antibody specific for human eIF-2a have also been
unsuccessful.
Because the kinase remains activated in an SV40-sub720
coinfection, as it does in a sub720 infection, it has the capacity
to phosphorylate eIF-2. However, because protein synthesis
proceeds as normal in these cells, it would seem that the eIF-2
would occur in its natural unphosphorylated state. One possi-
ble mechanism by which large-T antigen could neutralize the
effects of PKR would be by dephosphorylation of eIF-2. Pro-
tein synthesis would then continue at normal levels, despite the
activation of PKR. For example, by activating a phosphatase,
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large-T antigen could directly or indirectly dephosphorylate
the eIF-2 as it is phosphorylated by PKR. Although several
functions have been attributed to the large-T protein, a phos-
phatase function is not included in its repertoire. As shown in
Fig. 6 and 7, and as will be discussed below, the translation
complementation function localizes to a large portion of the
C-terminal half of the large-T protein molecule (amino acids
401 to 650). It is possible that the large-T protein itself pos-
sesses a phosphatase function that we have localized to this
region, or that the large-T antigen is acting via an intracellular
phosphatase by increasing either its activity or expression. Our
studies with the protein phosphatase inhibitor OA indicate
that treatment of COS cells 1 h after sub720 infection, provid-
ing sufficient time for infection to take place, causes inhibition
of the large-T-mediated translational complementation phe-
notype. OA can inhibit both PP2A and PP1 in vitro, depending
on the concentration (11). Because it is extremely difficult to
quantitate the intracellular concentrations of OA in our exper-
imental system, we cannot at this point define the source of the
phosphatase activity in our experiments based on OA inhibi-
tion. Also, the fact that OA treatment does not hamper protein
synthesis of WT Ad indicates that normal cellular translation is
not affected by OA treatment, while the SV40 large-T-medi-
ated translational control is affected. While these results hint at
the possibility that a phosphatase may be involved, our data at
present are not strong enough to argue that this may be the
sole basis for the translational complementation by the large-T
antigen.
Another mechanism that could explain large-T-mediated
translational complementation is based on the phosphoryla-
tion of GEF. This is a large, 5-subunit complex present at very
low stoichiometric concentrations in the cell. It functions in the
exchange of GDP for the GTP moiety on the a subunit of
eIF-2 at the end of every round of protein synthesis initiation
(reviewed in reference 42). Phosphorylation of the largest sub-
unit of GEF results in an increase in the exchange activity of
the GEF complex (22). It is thus possible that, during SV40
infection, phosphorylation of the GEF subunit might cause the
few free GEF complexes to function at increased efficiency,
thereby compensating for the bulk of GEF that is in the form
of inactive complexes with the phosphorylated eIF-2 in the cell.
Large-T antigen has also been shown to have an RNA helicase
function in vitro (45). During the initiation of translation, eIF-
4A, eIF-4B, and eIF-4F are thought to function as a complex
in the unwinding of the secondary structure of the mRNA
before it complexes with the ribosome (26). Currently, it is not
possible to determine the role of RNA helicase activity in the
translation complementation function because no information
is available for the RNA helicase domain.
Our mutational analysis of the SV40 large-T gene indicates
that the C-terminal half of the large-T protein is important for
the manifestation of the translation complementation pheno-
type. Because the translational complementation function of
large-T antigen maps to a reasonably large region of the pro-
tein, it is likely that this function may depend on the protein
conformation in this region or on multiple activities of the
large-T antigen. However, it does not overlap with the Ad
helper function because the C-terminal deletion mutants that
lack the Ad helper function complement for the VAI RNA
function in transient transfection assays. The 82 N-terminal
amino acids of the protein do not seem to be important, as the
complementation occurs in the absence of small-t antigen.
Also, a large part of the N-terminal region of large-T antigen
may not be involved in the complementation function because
a number of mutants with deletion, substitution, and insertion
mutations in this region are able to rescue the sub720-specific
translational defect. Mutants with mutations encompassing
amino acids 401 to 650 were defective in the complementation
assay, indicating that the complementation function maps to
this region. Although the amount of hexon that we see in the
complementation assays is related to the amount of large-T
protein present in the cell during the assay, lack of comple-
mentation for mutants 601/650, 451/500, and 401/450 cannot be
explained by the lack of sufficient quantities of T antigen in the
cell. Mutants dl1263 and dl2459 also synthesize large-T antigen
in quantities comparable to those of dl601/650, dl401/450, and
dl451/500 (Fig. 6B), yet they are able to rescue the translational
defect (Fig. 6A). Thus, we believe that these three deletion
mutants are truly defective for the complementation function.
Several important functions of the protein reside in this region,
including ATPase activity, ATP binding, p53 binding, and
DNA helicase activity (16). Mutants dl2827 and dl2432 are
defective in ATPase activity yet can complement the sub720
phenotype, indicating that ATPase activity is not involved in
the complementation function. The observation that large
amounts of phosphorylated PKR can be detected in cells coin-
fected with sub720 and SV40, despite the ATPase activity of
large-T antigen, is consistent with this finding. The activation
of PKR involves ATP-dependent autophosphorylation. If the
ATPase activity of large-T antigen had any role in the comple-
mentation function, it is possible that this would have impacted
upon the autophosphorylation of PKR.
The region of large-T antigen that is essential for comple-
mentation also binds to p53. However, we believe that the
translation complementation function is not related to large-T
antigen’s association with p53. Of the three mutants which fail
to complement, mutants 401/450 and 601/650 do not bind p53
whereas mutant 451/500 does (30). Mutant 402DH, which car-
ries a point mutation at amino acid 402, also does not bind p53
(50a) yet suppresses the sub720 phenotype, commensurate
with its poor stability. Another activity associated with this
region is DNA helicase activity. It is unlikely that the DNA
helicase function would be important in translational regula-
tion. The role of the RNA helicase function of the large-T
antigen in complementation cannot be addressed genetically
because this function has not yet been mapped to a domain on
the protein. With the helper-defective deletion mutants, we
have also shown that the translational regulation property of
the large-T antigen is not a part of the Ad helper function of
SV40, suggesting that the translational complementation func-
tion is a novel function which is not associated with previously
described functions of large-T antigen.
Cellular defense mediated by interferon-induced PKR is a
problem that viruses must overcome in order to establish suc-
cessful infection. Different viruses use different strategies to
overcome the PKR effect (28, 36, 47). Several strategies have
been described, and many more probably exist. Viruses use
both proteins and RNAs to antagonize the effects of PKR. As
discussed above, VAI RNA directly binds to and blocks the
activation of PKR. The Epstein-Barr virus-encoded EBERs
(13) and the human immunodeficiency virus TAR RNA (20)
can stimulate translation in vitro in reticulocyte lysates, pre-
sumably by inhibiting the activation of PKR. EBERs can com-
plement the VAI RNA function in the Ad chromosome, indi-
cating that they may function like VAI RNA (5, 7), although
rigorous proof that they are functionally equivalent to VA
RNAs is lacking (52). Human immunodeficiency virus type 1
tat protein reduces the amounts of PKR by an unknown mech-
anism (41), whereas poliovirus degrades PKR (8). Influenza
virus can inhibit PKR activation indirectly via a host protein
(34). Vaccinia virus-encoded E3L (1, 10) and reovirus sigma 3
(25) gene products have the capacity to bind to double-
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stranded RNA and thus are able to inhibit the activation of
PKR. In all these cases, the end result is reduction of active
PKR in the cell. Our results show that the SV40 large-T gene
product counteracts the inhibitory effects of PKR downstream
of the PKR activation step, possibly by activation or induction
of phosphatases that may dephosphorylate eIF-2. The other
possibility, that the large-T protein may mimic the a subunit of
eIF-2 and thus inhibit phosphorylation of eIF-2, cannot be
ruled out at present. Indeed, such a mechanism has been
proposed for the vaccinia virus-encoded K3L gene product in
the neutralization of the PKR effect (15). Further work will be
necessary to define the molecular mechanism by which large-T
antigen may antagonize the deleterious effects of the activation
of PKR.
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